Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2007

View Archived Issues

Novel therapeutic agents for thrombotic and other blood coagulation disorders reported in patents

Heat shock protein 70 gene therapy safe, effective in phase I cancer study

Favorable endometrial profile seen with bazedoxifene in postmenopausal women

Progress on gene therapies reported

THCV begins phase I for obesity and metabolic disorders

Eurand and GSK reach milestone in orally disintegrating tablet collaboration

Sunesis earns milestone on progress of novel LFA-1 inhibitor candidate

MAGE-A3 cancer immunotherapeutic begins phase III study in NSCLC

Novel analgesic agents imparted in recent patent literature

New treatment options for neurological disorders reported in recent patent literature

Phase III enrollment stopped for SECTA therapy on DMC advice

Further development of XTL-2125 suspended

Interim RECORD data support Avandia safety; FDA requests more prominent product labeling

M-0002 begins phase IIa study in ascites

SLx-4090 studied in new phase IIa for dyslipidemia

Modulation of purinergic P2X and P2X2/3 receptors, a new strategy for treating urinary incontinence

Indigo inlicenses drug for treatment of arteriosclerosis obliterans

Amgen to acquire Alantos

CYT-107 to begin phase I/IIa trials in hepatitis C and oncology

Oral laquinimod to begin phase III program in relapsing MS

PF-562271 associated with activity and manageable toxicity in ongoing phase I trial

Tapestry's third-generation taxane TPI-287 advances through the pipeline

Targeted chemotherapeutic EC-145 advances to phase II clinical trials

Ongoing phase I clinical trials evaluating different dose schedules of E-7974

Antisense p53 production inhibitor improves efficacy and tolerability of cytarabine/idarubicin

Actemra significantly improves signs and symptoms of rheumatoid arthritis

AN-2728 shows comparable efficacy to betamethasone and tacrolimus in psoriasis

Japanese priority review for Taxotere in hormone refractory prostate cancer

E.U. approval for Humira for severe Crohn's disease

Remicade approved in E.U. for pediatric Crohn's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...